PFE vs TOI

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Score Change Explanation: The increase from 18/100 to 29/100 is primarily driven by the reported Q1 2026 earnings, where TOI significantly beat both revenue and EPS consensus estimates ($147.44M vs $142.10M, and -$0.02 vs -$0.07). This positive earnings surprise, along along with the provision of updated FY2026 revenue guidance ($630M-$650M) and a material open-market purchase by a 10% owner (Cher...